This Gene Therapy Stock Cracked the Code in Myotonic Dystrophy

A rare neuromuscular disease with no approved treatment just saw its most promising trial result yet.

This microcap presents data showing over 50% splicing correction and a clear dose response, a major inflection point in gene therapy.

On Behalf of The FUTR Corp.

Investors who jumped on C3.ai or SoundHound watched them hit multi-billion-dollar valuations almost overnight.

But let’s be honest… you probably missed that wave.

Here’s the good news: the next one could be even bigger.

Not chatbots. Not voice bots.

AI Agents.

Assistants that act, not just talk. They scan bills, pay them, flag renewals, and reward users for sharing data.

One overlooked small-cap already has the rails in place:

Zero-party data is about to flip the entire model. Consumers control it, license it, and finally get rewarded.

With this company powering transactions and a Utility Token driving access, every data exchange becomes a revenue event in a $4.4T market.

And in Q3 2025, this tiny under-the-radar company is launching their consumer AI agents.

This could be the iPhone moment of AI, and most of Wall Street hasn’t noticed yet.

Click here now to see the name and stock symbol.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Wall Street slipped further as stronger-than-expected GDP and jobless claims data dimmed hopes for aggressive Fed rate cuts, pressuring valuations near record highs.

Starbucks (NASDAQ: SBUX) has just announced a $1 billion restructuring plan that includes closing underperforming cafes and cutting approximately 900 jobs.

The move takes North America's store count down by roughly 1%, but the company insists it's about quality over quantity.

For a chain with more than 18,000 cafes across the U.S. and Canada, losing a few hundred won't dent the brand's presence.

Why the Espresso Shot Matters

The coffee giant has been dragging through six straight quarters of sales declines.

Pricey lattes aren't selling as quickly as they used to, and customers are becoming more discerning with both price and experience.

That's where this restructuring comes in.

By slimming down management layers and reinvesting in store operations, Starbucks is betting faster service and better vibes will lure people back.

Should You Bet on the Comeback?

Here's the question: is this a warning sign, or a smart reset? On the one hand, trimming jobs and closing stores shows that Starbucks acknowledges it has a problem.

On the other hand, it remains massive, global, and profitable enough to invest significantly in improvements.

If you're evaluating the business, this isn't a bad sign.

It's Starbucks acknowledging it needs some adjustments, and sometimes that's exactly what prevents a major brand from becoming stale.

Amazon (NASDAQ: AMZN) has agreed to pay $2.5 billion to settle claims that it tricked people into signing up for Prime.

About $1.5 billion of that goes into a fund to reimburse millions of shoppers who were stuck with subscriptions they didn’t want.

The wild part? Amazon isn’t admitting any wrongdoing. It’s just writing a massive check, promising to behave, and moving on.

For a company that generates billions every quarter, this is more akin to a traffic ticket than a life sentence.

Making “Cancel” Finally Mean Cancel

As part of the deal, Amazon has to build a real button that clearly lets you say no to Prime.

No more hiding behind pop-ups, extra steps, or mysterious “are you sure?” screens that made cancelling feel like a maze.

They’ll also have an outside watchdog making sure the new rules stick.

If you’ve ever felt like Amazon treated “unsubscribe” as a challenge instead of an option, the FTC just handed you the win.

Should You Worry?

Here’s the simple way to see it: $2.5 billion sounds huge, but for Amazon, it’s barely a speed bump.

The company is still raking in billions from cloud, ads, and e-commerce, and those engines aren’t slowing down.

So if you’re thinking about the stock, this isn’t a “sell everything” moment. It’s more like Amazon paying a fine and getting right back to business.

The Prime button may change, but the money machine behind it won’t.

When markets shift, opportunities emerge. But the best ones rarely stay hidden for long.

Our analysts have pinpointed 5 companies that stand out for their fundamentals, momentum, and potential to double from here.

You’ll find them inside the new 5 Stocks Set to Double report—free for a limited time.

Past versions of this report uncovered stocks that went on to massive gains of +175%, +498%, even +673%.¹

Today, you can download your copy instantly.

But once the clock strikes midnight, this free access closes.

[Grab your free report now]

Big winners don’t wait. Neither should you.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Accenture (NYSE: ACN) just beat revenue estimates, but the real news is an $865 million restructuring plan.

That means job cuts, selling off side projects, and reinvesting the savings into training workers for the AI boom.

It’s not a retreat, it’s a reset. The company is basically swapping out old parts and tuning up the engine so it can run faster in the digital future.

Training Over Talk

A big chunk of that money is going straight into teaching employees new skills.

Instead of just talking about AI, Accenture wants teams that can actually deliver AI-powered solutions. That’s not cheap, but it could make them stand out in a crowded field.

At the same time, the firm is still hiring in key spots, showing it’s not shrinking away. It’s just trimming what doesn’t work and doubling down where demand is exploding.

What It Means for You

Think of it this way: Accenture is paying a steep bill now so it doesn’t fall behind later.

It stings in the short term, but the payoff could be a company that’s leaner, sharper, and ready to ride the AI wave instead of chasing it.

You don’t need a finance degree to get it — the company is basically trading today’s comfort for tomorrow’s edge.

If the bet pays off, Accenture walks away as one of the big winners in the next phase of digital growth.

👉 Click here to get our closing report to your cell for free!

PepGen Inc [PEPG] $5.83 (+118.99%)

PepGen surged after reporting 53.7% splicing correction at its highest tested dose in DM1 patients, showing clear dose-dependent efficacy in a rare neuromuscular disease with no treatment.

SciSparc Ltd [SPRC] $6.09 (+59.01%)

SciSparc jumped after launching a quantum computing initiative to model 3D protein structures, aiming to revolutionize drug discovery for neurological and rare diseases.

Dario Health Corp [DRIO] $13.69 (+42.75%)

DarioHealth gained after announcing a strategic review, citing multiple unsolicited offers and a strengthened balance sheet as it explores potential M&A opportunities.

Super League Enterprise Inc [SLE] $5.19 (-30.52%)

Super League pulled back as crypto markets slumped sharply this week, souring sentiment on its Evo Fund-backed digital asset strategy.

CarMax Inc [KMX] $45.62 (-20.04%)

CarMax sank after missing Q3 earnings and revenue estimates, with same-store sales dropping and margins tightening amid soft used-car demand.

Immuneering Corp [IMRX] $8.00 (-13.33%)

Immuneering dropped after pricing a $175 million public offering at a sharp discount, diluting existing shareholders despite strong cancer trial data.

With built-in tech to launch and scale viral gear, this company isn't following trends-it's setting them.

A recent equity deal with Alabama just lit the fuse.

Find out how this model is built to dominate before Wall St. catches on

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.